RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $591.43 million. The enterprise value is $366.50 million.
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 40.62 million shares outstanding. The number of shares has increased by 12.81% in one year.
| Current Share Class | 40.62M |
| Shares Outstanding | 40.62M |
| Shares Change (YoY) | +12.81% |
| Shares Change (QoQ) | +1.43% |
| Owned by Insiders (%) | 4.94% |
| Owned by Institutions (%) | 77.16% |
| Float | 32.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.04 |
| Forward PS | 3.17 |
| PB Ratio | 2.09 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.36 |
| Quick Ratio | 10.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,755.14 |
Financial Efficiency
Return on equity (ROE) is -12.43% and return on invested capital (ROIC) is -10.08%.
| Return on Equity (ROE) | -12.43% |
| Return on Assets (ROA) | -9.19% |
| Return on Invested Capital (ROIC) | -10.08% |
| Return on Capital Employed (ROCE) | -12.59% |
| Revenue Per Employee | $280,978 |
| Profits Per Employee | -$55,131 |
| Employee Count | 498 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.08 |
Taxes
In the past 12 months, RxSight has paid $50,000 in taxes.
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.39% in the last 52 weeks. The beta is 1.25, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -72.39% |
| 50-Day Moving Average | 22.75 |
| 200-Day Moving Average | 39.30 |
| Relative Strength Index (RSI) | 27.96 |
| Average Volume (20 Days) | 1,316,345 |
Short Selling Information
The latest short interest is 3.66 million, so 9.02% of the outstanding shares have been sold short.
| Short Interest | 3.66M |
| Short Previous Month | 3.15M |
| Short % of Shares Out | 9.02% |
| Short % of Float | 11.32% |
| Short Ratio (days to cover) | 3.31 |
Income Statement
In the last 12 months, RxSight had revenue of $139.93 million and -$27.46 million in losses. Loss per share was -$0.71.
| Revenue | 139.93M |
| Gross Profit | 98.94M |
| Operating Income | -36.86M |
| Pretax Income | -36.75M |
| Net Income | -27.46M |
| EBITDA | -33.28M |
| EBIT | -36.86M |
| Loss Per Share | -$0.71 |
Full Income StatementBalance Sheet
The company has $237.22 million in cash and $12.30 million in debt, giving a net cash position of $224.93 million or $5.54 per share.
| Cash & Cash Equivalents | 237.22M |
| Total Debt | 12.30M |
| Net Cash | 224.93M |
| Net Cash Per Share | $5.54 |
| Equity (Book Value) | 281.24M |
| Book Value Per Share | 6.96 |
| Working Capital | 267.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.95 million and capital expenditures -$5.44 million, giving a free cash flow of -$22.39 million.
| Operating Cash Flow | -16.95M |
| Capital Expenditures | -5.44M |
| Free Cash Flow | -22.39M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
Gross margin is 70.71%, with operating and profit margins of -26.34% and -19.62%.
| Gross Margin | 70.71% |
| Operating Margin | -26.34% |
| Pretax Margin | -19.59% |
| Profit Margin | -19.62% |
| EBITDA Margin | -23.79% |
| EBIT Margin | -26.34% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.81% |
| Shareholder Yield | -12.81% |
| Earnings Yield | -4.64% |
| FCF Yield | -3.79% |
Dividend DetailsAnalyst Forecast
The average price target for RxSight is $38.50, which is 164.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $38.50 |
| Price Target Difference | 164.42% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 20.91% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 29.64 and a Piotroski F-Score of 4.
| Altman Z-Score | 29.64 |
| Piotroski F-Score | 4 |